Cornucopian Capital’s Post

Looking forward to talking about how rapid weight loss affects the musculoskeletal system.

Our researchers are investigating a potential target known as Factor XIa that may help advance care for people at risk of thrombotic events, like stroke, in our Phase 3 Librexia program with Johnson & Johnson Innovative Medicine. Learn more about the potential of FXIa and how we’re aiming to improve outcomes for patients living with thrombotic conditions: https://bit.ly/3zVT4ix #WorldStrokeDay #OneBMS

Dr. Menard explains his experience and findings with the BEST-CLI clinical trial to understand treatment options for patients with CLTI. Watch the DeBakey Bytes video below to learn more https://lnkd.in/gv4Qd6Vj, or click the link below for the full-length presentation: https://lnkd.in/gd5g4W3U

I had the privilege of presenting our research at the ESC Congress in London, focusing on the impact of iron deficiency definitions on prognoses in patients with heart failure. Our key finding was that the prevalence of iron deficiency in heart failure patients significantly varies depending on the definition used. Notably, we observed that iron deficiency, when defined by transferrin saturation (TSAT) <20% or serum iron ≤13 µmol/L, is associated with an increased risk of mortality and hospitalization due to heart failure. This highlights the critical need to carefully consider how we define and diagnose iron deficiency in clinical practice, as it could have profound implications on patient outcomes. Thanks to my co-authors for their contributions to this work. Gunnar Gislason (main supervisor) Daniel Mølager Christensen Milan Mohammad Morten Schou Morten Lock Hansen Mariam Elmegaard Nina Nouhravesh Christian Torp-Pedersen Tor Biering-Sørensen, MD, MSc, MPH, PhD Emil Loldrup Fosbøl Charlotte Andersson Lars Køber #HeartFailure #IronDeficiency #ESCCongress2024 #CardiologyResearch

#CVCT2024 : A significant advancement has been made in the field of traditional Chinese medicine (TCM) for heart failure treatment. Publication on Nature Medicine, focused on the QUEST study, highlights the efficacy and safety of the Qiliqiangxin (QLQX) capsule in treating patients with heart failure with reduced ejection fraction (HFrEF). The trial included 3,110 patients and demonstrated that QLQX, when added to standard treatment, significantly lowered the incidence of major adverse cardiovascular events by 22%. Join the discussion December 9-11, Washington DC : https://lnkd.in/dXSEJhZB David Goff, Carolyn Lam, Li-Ming Gan, Chokri Jeribi, Kazuomi Kario, Felipe Martinez, Sangeetha Anand, Ken Stein, agustina bisio, Manabu Minami, Harlan Krumholz #CVCT #globaltrials #clinicalresearch #clinicaltrials

"On #WorldHeartDay, we're committed to advancing clinical research that drives innovative solutions for heart health. At Insignia, we prioritize cardiovascular research to ensure healthier futures for all. Every beat counts, and so does every trial. ❤️ #HeartHealth #ClinicalResearch #WorldHeartDay #CRO"

Secure your spot for the latest in Osteoarthritis research with Dr. Matlock Jeffries and Dr. Rachel E. Miller, both respected ANRF alumni. Join us to delve into symptom management, treatment options, and groundbreaking research in the field. https://ow.ly/UZrr50TQnCY

Dr. Philip Mease is the Director of the Division of #Rheumatology Research at Swedish Medical Center/Providence Saint Joseph Health and a clinical professor at the University of Washington in Seattle. In this SiM course, Dr. Mease discusses axial psoriatic arthritis: what does it look like clinically, how does it differ from axial spondyloarthritis, and how should it be diagnosed and treated. Learn more: https://lnkd.in/dgGHktiZ

This September, National Atrial Fibrillation Awareness Month reminds us to stay sharp about heart health and the impact of AFib. Atrial fibrillation, a common but serious heart rhythm issue, can lead to strokes and other complications if ignored. Millions are affected, and this month is all about spreading the word, learning the risks, and pushing for better management and care. Big pharma giants like Abbott Laboratories, Johnson & Johnson, Boston Scientific, Medtronic, and Siemens Medical Solutions AG, and others are leading the charge with cutting-edge treatments and tech to help patients live better with atrial fibrillation. Their innovation is moving the needle towards more effective care, offering hope for those affected by this condition. Let’s come together this month to boost awareness, support ongoing research, and encourage everyone to take heart health seriously. Small steps in understanding AFib can make a big difference. Let’s get the conversation going and make strides for a healthier tomorrow! #AFibAwareness #HeartStrong #HeartHealthMatters #AtrialFibrillation #StayInformed #HealthBreakthroughs #SupportResearch #HealthyHeartJourney #FightAFib #HeartCareMatters #HopeForHealthierHearts

The 17th SCWDConference is Live Now! Is GLP-2 treatment a potential clinical opportunity to reverse muscle wasting? During session B at the 17th #SCWDConference2024 in Washington DC, experts are exploring the role of GLP-2 treatments in addressing muscle wasting associated with sarcopenia and cachexia. Stay tuned for the latest insights on this evolving topic as we delve into clinical research & best practices. #Sarcopenia #Cachexia #MuscleWasting #GLP2 #SCWD2024